Wednesday, October 7, 2026

Strategy Raises STRC Dividend to 12%, Adds $2B Buyback as Bitcoin Premium Turns Negative

Strategy's mNAV — the premium investors pay over its Bitcoin holdings — has dropped below 1, forcing a capital overhaul. The Virginia-based firm hiked its STRC preferred dividend to 12%, authorized a $2 billion buyback, and began selling Bitcoin as global regulators simultaneously tighten scrutiny of stablecoins.

LM Salvado
LM Salvado

July 16, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Strategy Raises STRC Dividend to 12%, Adds $2B Buyback as Bitcoin Premium Turns Negative
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Strategy's market-to-net-asset-value premium has fallen below 1, signaling investors worldwide are pulling back from its leveraged Bitcoin-accumulation model. The US firm is now restructuring its capital framework in response.

Strategy raised its STRC preferred dividend to 12% to retain capital and hold investors as the mNAV slide continued. It also authorized a $2 billion share buyback and launched a monetization program, moving beyond a strategy built solely on accumulating Bitcoin.

Chairman Michael Saylor sold a small amount of Bitcoin as part of the shift — notable given his years-long public refusal to sell. Bitcoin ETFs recorded $4 billion in outflows over the same month, a signal that institutional caution extends well beyond one company.

Regulators outside the US are moving in parallel. The Bank for International Settlements, the Basel-based institution that coordinates central banks globally, cast doubt on stablecoins' status as money in its annual report, arguing they function more like exchange-traded fund shares than a payment instrument.1 The BIS said stablecoins "trade off par" and show "redemption frictions... which we've literally never seen," adding they "don't settle on central bank balance sheets and can't guarantee par across issuers."1

The BIS also warned that dollar-denominated stablecoins are accelerating dollarization in fragile economies, weakening local currencies and undermining capital controls — a concern echoed by central banks in Latin America, Africa and parts of Asia. "You can't enforce border rules on a self-custodied token," the institution said.1

The two developments are linked. Corporate Bitcoin treasuries built on leverage and premium valuation are showing their first real strain, while global regulators signal tighter scrutiny of the stablecoin infrastructure underpinning much of the crypto market worldwide. For Strategy, the overhaul marks a departure from its identity as a pure Bitcoin-accumulation vehicle toward one managing shareholder returns directly through dividends and buybacks — a shift international investors will watch as a bellwether for corporate crypto-treasury strategies globally.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· June 29, 2026
    Saylor's Strategy changes playbook and can now sell its bitcoin

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com